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Mesenchymal stem cells (MSCs) have been used for therapy of type 1 diabetes mellitus. However, the in vivo distribution
and therapeutic effects of transplanted MSCs are not clarified well. Herein, we reported that CdSe/ZnS quantum
dots-labeled MSCs were prepared for targeted fluorescence imaging and therapy of pancreas tissues in rat
models with type 1 diabetes. CdSe/ZnS quantum dots were synthesized, their biocompatibility was evaluated,
and then, the appropriate concentration of quantum dots was selected to label MSCs. CdSe/ZnS quantum dots-labeled
MSCs were injected into mouse models with type 1 diabetes via tail vessel and then were observed by using the Bruker
In-Vivo F PRO system, and the blood glucose levels were monitored for 8 weeks. Results showed that prepared CdSe/
ZnS quantum dots owned good biocompatibility. Significant differences existed in distribution of quantum
dots-labeled MSCs between normal control rats and diabetic rats (p < 0.05). The ratios of the fluorescence intensity (RFI)
analysis showed an accumulation rate of MSCs in the pancreas of rats in the diabetes group, and was about 32 %, while
that in the normal control group rats was about 18 %. The blood glucose levels were also monitored for 8 weeks after
quantum dots-labeled MSC injection. Statistical differences existed between the blood glucose levels of the
diabetic rat control group and MSC-injected diabetic rat group (p < 0.01), and the MSC-injected diabetic rat group
displayed lower blood glucose levels. In conclusion, CdSe/ZnS-labeled MSCs can target in vivo pancreas tissues in
diabetic rats, and significantly reduce the blood glucose levels in diabetic rats, and own potential application in
therapy of diabetic patients in the near future.
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The amount of diabetic patients has been increasing rap-
idly. According to the latest report, in China, the pro-
portion of diabetic patients has reached to 11.6 %,
accounting for one third of global diabetic patients. How
to prevent and treat diabetes has become a challengeable
problem. Type 1 diabetes mellitus is characterized by
the permanent destruction of pancreatic β cells. Symp-
tomatic individuals typically have lost more than 80 % of
β cell population, resulting in essentially no insulin pro-
duction and an inability to regulate plasma glucose levels
properly [1].
Up to date, regarding the therapy of type 1 diabetes,
some methods have been reported. For example, cell-
based treatments with the aim of recovering pancreatic
β cell function, including the pancreas transplantation,
islet transplantation, and stem cell transplantation, fo-
cusing on replacing damaged β cell populations, should be
the ideal potential therapeutic pathways [2]. Among the
cell-based treatments, the current gold standard is whole-
pancreas transplantation. Recent pancreas transplants
have demonstrated sustained exogenous insulin independ-
ence over 2 years post-transplant, evidenced by normal
HbA1c values. However, pancreas transplantation is a
major surgical procedure with mortality rates ranging
from 1 to 3 %, and the complications of the procedure re-
quired long-term immunosuppression [3]. In order to
overcome these shortcomings of whole-organ transplant-
ation, pancreatic islet cells transplanting has been actively
explored. In 2000, a corticosteroid-free immunosuppres-
sive regimen, the novel Edmonton protocol, enabled seven
patients to remain insulin-independent for an average of
11.9 months [4]. However, these results are quite difficult
to reproduce, and nine-year islet graft survival rates are
below 10 %. Therefore, looking for new therapeutic
method may be a good choice.
Stem cell transplantation for diabetes therapy may
offer a promising possibility that deserves to be ex-
plored. Stem cell transplantation has some advantages,
such as the easy operation, short operation time, and
low invasiveness for patients relatively compared with
whole-organ transplantation [5]. Up to date, mesenchy-
mal stem cells (MSCs) have been actively investigated
for their therapeutic values on different kinds of diseases
such as diabetes, injury, gastric cancer, etc. The benefit
of MSCs, including multi-lineage differentiation and im-
munosuppressive capability, suggests a role of MSC
therapy for tissue regeneration [6]. However, the distri-
bution and therapeutic effects of transplanted MSCs in
diabetic patients are not clarified well.
In recent years, nanotechnology has become an emer-
ging field of interest. Interaction studies between nano-
materials and stem cells have made great advances. The
importance of nanotechnology to the fundamentaldevelopments in stem cell-based therapies for injuries
and degenerative diseases has been recognized. In par-
ticular, the effects of the structure and properties of
nanomaterials on the tracing of stem cells have become
a new interdisciplinary frontier in regeneration medicine
and material science.
Quantum dots (QDs) are one kind of nanomaterial
which have broad application prospects in cellular im-
aging, immunoassays, DNA hybridization, and optical
barcoding, due to its significant advantages including
good photostability, strong fluorescence intensity, and
various emission wavelengths. As QDs were broadly
used for molecular imaging, QDs biocompatibility at-
tracts more and more attention from the scientific field.
Exploration of quantum dots biosafety has become a
hotspot. In another aspect, QDs with near-infrared re-
gion (NIR) emission have also received increasing atten-
tion as an alternative method for overcoming these
shortcomings [7, 8].
In our previous study, we have synthesized CdSe/ZnS
QDs with near-infrared region [9]. Herein, we evaluated
the biosafety of CdSe/ZnS QDs and investigated the
in vivo biodistribution and the effects of CdSe/ZnS
QDs-labeled MSCs on plasma glucose levels in type 1
diabetes rat models. Our study lays foundation for MSC
clinical application for diabetes therapy in the near
future.
Methods
All animal experiments were approved by the Institutional
Animal Care and Use Committee of Shanghai Jiao Tong
University (NO. SYXK2007-0025).
Synthesis and Characterization of CdSe/ZnS QDs
CdSe/ZnS QDs were synthesized according to our previ-
ous report [9]. Briefly, with the nitrogen protection, 79-mg
selenium powder was dissolved in 50-ml liquid paraffin in
a three-neck flask and the temperature was increased to
200 °C gradually. After vigorous stirring for 1 h, the mix-
ture was cooled to 80 °C. In another flask, 1.28-g CdO and
11.4-g stearic acid were dissolved in 10-ml liquid paraffin
at 160 °C with stirring and protection of nitrogen. When
the mixture turned to bright yellow, the cooled solution of
Se precursors was rapidly injected into the hot flask con-
taining Cd precursors and the mixture temperature was
quickly increased to 200 °C for 90 min. The molar ratio of
CdO/Se/stearic acid in liquid paraffin was 1:1:4, and the
crude QD products were purified by chloroform and etha-
nol. In order to improve the optical properties of QDs, an
additional semiconductor shell (zinc sulfide (ZnS)) should
be coated on CdSe nanocrystals. For the ZnS shell, equal
molar ratios of (TMS)2S and ZnEt2 as precursors of Zn
and S and TOP/TOPO were used, and 90 °C was used for
shell growth. The final core–shell product was repurified
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About 10 ml of deionized water was added to the solu-
tion to prevent evaporation of chloroform for long-
period storage.
Primary Culture and Identification of Rat MSCs
MSCs were isolated according to our previous reports
and were cultured with Dulbecco’s modified Eagle’s
medium (DMEM; Gibco, Shanghai, China) with 10 %
fetal bovine serum (FBS; Hyclone, Thermo Scientific,
Logan, UT, USA), 100 U/ml penicillin, and 100 mg/ml
streptomycin (Gibco) at 37 °C in a humidified 5 % CO2
incubator. The MSC medium was changed once every 2
days. The primary cells were cultured for 4 ~ 5 days until
they reached confluence and were defined as passage“0”.
All experiments were performed with the MSCs from
passage 3–6. In order to identify MSCs, passage 4 MSCs
were detached by 0.25 % trypsin/EDTA and washed twice
with phosphate buffered saline (PBS). About 2 × 105 cells
were incubated with an appropriate concentration of
FITC-conjugated CD29 monoclonal antibody (BioLegend,
San Diego, CA, USA), phycoerythrin (PE)-conjugated
CD31 monoclonal antibody (BioLegend), APC-conjugated
CD45 (BioLegend), and PE-conjugated CD90 (BioLegend)
monoclonal antibody for 40 min at 4 °C in a dark envir-
onment. MSCs were washed with PBS buffer, were cen-
trifuged for 5 min, and then resuspended in PBS.
Quantitative fluorescence analysis was carried out using
FACSCalibur cytometer (Becton Dickinson, San Diego,
CA, USA) and CellQuest software.
In order to demonstrate the multipotential property of
our prepared MSCs, MSCs were further characterized by
differentiation assays. Passage 3 MSCs were cultured in an
adipogenic medium including DMEM, 5 % FBS, 1-μM
dexamethasone (Sigma), 50-μM indomethacin (Sigma),
500-nM IBMX (Sigma), 5 μg/ml insulin (Sigma), 100 U/
ml penicillin, and 100 mg/ml streptomycin for about 2
weeks [9]. The medium was replaced every 3 days with a
fresh induction medium. Subsequently, to evaluate cul-
tures for adipogenic differentiation, the cells were washed
with PBS, fixated with 2.5 % glutaraldehyde, and stained
with Oil Red O (Sigma) for revealing lipid globules. In
addition, passage 3 MSCs were cultured in DMEM sup-
plemented with 5 % FBS, 50-μM ascorbic acid (Sigma),
10-nM dexamethasone, 100 U/ml penicillin, and 100 mg/
ml streptomycin for about 2 weeks for osteogenic differen-
tiation. Finally, the cells were evaluated and cultured for
osteogenic differentiation with Alizarin Red S (Sigma).
Effects of CdSe/ZnS QDs on the Differentiation Ability of
MSCs
In order to estimate the changes of MSCs’ differential
ability under the condition of CdSe/ZnS, the differenti-
ation experiments were carried out with or without theCdSe/ZnS QDs (16 μg/ml), and the morphology of the
final differentiation cells were captured in microscopy
and compared.
Cell Viability Assay
Toxicity test is determined by the cell viability after in-
cubation in a culture medium containing different con-
centrations of CdSe/ZnS QDs. A controlled trial was
conducted by culturing cells in a normal medium with-
out QDs. We carried out this test by using Cell Count-
ing Kit-8 (CCK-8) which is an upgrade alternative to
MTT assay. This toxicity assay was performed in a 96-
well plate with about 1 × 103 cells seeding in every well.
After incubating in a culture medium containing differ-
ent concentrations (concentration = the volume of QDs/
the volume of medium, the unit is μl/ml)of QDs for 24
h, the CCK-8 reagent (10 μl) was added to each well and
there, action was allowed to proceed for up to 4 h. The
optical absorbance was measured at 450 nm by using
the Thermo multiskan MK3 ELISA plate reader accord-
ing to the protocol of the CCK-8 assay kit.
Transduction of Different Concentrations of QDs into
MSCs
MSCs were cultured in the medium without FBS at 37 °C,
in 5 % CO2 for 4 h, and different amounts of of
QDs(100μg/ml) (5.0, 10.0, 15, and 20 μl/ml) were
mixed in the transduction medium (DMEM, 10 % FBS,
100 U/ml penicillin/streptomycin) at 37 °C for 15 min,
respectively; the medium was added into the MSC cul-
ture flask, incubated in a humidified 5 % CO2 incubator
at 37 °C for 6 h. And then, the flask was washed three
times with PBS and covered with new PBS. The cells
were counted and prepared for quantum dot distribu-
tion test and cell transplantation.
The Distribution of the Quantum Dots in MSCs
Passage 3 MSCs were treated with a medium containing
CdSe/ZnS QDs (15 μl/ml) for 4 h. Afterward, the cells
were visualized under an inverted fluorescence micro-
scope (Olympus IX71, Olympus, Shanghai, China). After
incubation with QDs, the cells were fixed with parafor-
maldehyde for 15 min at room temperature. The labeled
MSCs were also stained with 4′,6-diamidino-2-phenylin-
dole (DAPI) in PBS (pH 7.4) for 5 min. And then, the
cells were washed with PBS. The cells were observed
with the fluorescence microscope. Fluorescence imaging
microscopy was equipped with 372- and 510-nm wave-
length excitation light filters.
Preparation of Diabetes Rat Models
Type 1 diabetes SD rat models were prepared according
to the previous report [4, 10]. Thirty specimens of eight-
week-old male rats were lightly anesthetized. The rats
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control group (n = 10), diabetic control group (n = 10),
and MSC treatment group (n = 10). Streptozocin (STZ,
Sigma–Aldrich S1030) was dissolved in 0.1-M citrate at
pH 4.5 and was immediately injected into the abdominal
cavities of the diabetic control group and MSC treat-
ment group at a dose of 60 mg/kg. The normal control
group received the same dose of citrate buffer injection.
One week later, fast plasma glucose (FPG) amounts of
all rats were examined, and those rats with plasma glu-
cose concentration FPG ≥ 16.5 mmol/l were considered
as diabetic rats.
CdSe/ZnS QDs-Labeled MSCs for Targeted Fluorescence
Imaging
At the seventh day after the diabetes rat models were
prepared, the MSCs (5.0 × 106 cells/rat) labeled with
QDs were injected into the rat models in the MSC treat-
ment group via tail vein, while the normal control group
rats received the same dose of QDs-labeled MSCs.
For in vivo imaging analysis, whole-animal imaging
was performed with the Bruker In-Vivo F PRO system.
The images of several time points (1, 3, 6, and 12 h)
post-injection of MSCs were captured and analyzed to
understand the migration and homing behavior of MSCs
in type 1 diabetes rats. The excitation and emission filters
were set to 410 and 700 nm (bandpass, ±15 nm), respect-
ively. The collected images were analyzed with the image J
software (NIH ImageJ; http://rsb.info.nih.gov/ij/), which
employs spectral algorithms to separate autofluorescence
from quantum dot signals. (The imaging condition is the
same of in vivo imaging.)
Distribution of CdSe/ZnS QDs-Labeled MSCs in Rats with
Type 1 Diabetes
For the ex vivo fluorescence imaging analysis, rats were
sacrificed by cervical detachment method at 6 h after
MSC injection (time point selection were accorded with
the homing effects of MSCs, data not shown), five or-
gans (heart, lungs, pancreas, spleen, and liver) of theFig. 1 Phase-contrast photo micrographs of cultures showing MSC lines at
MSCs showed diverse morphologies including ovoid, bipolar, and large, fla
MSCs exhibited large, flattened, or fibroblast-like morphologynormal control and MSC treatment groups were har-
vested, and the fluorescence images were captured by
the Bruker In-Vivo F PRO system. The excitation and emis-
sion filters were set to 510 and 700 nm (bandpass, ±15
nm), respectively. The collected images were analyzed with
the image J software.
The Measurement of Plasma Glucose Levels in Diabetes
Rat Models
Eight-week-old rats were administered with STZ, which
induced pancreatic injury and hyperglycemia. In order to
investigate the therapeutic effects of MSCs (unlabeled
with QDs), the level of blood glucoses from the 1st to
the 8th week after MSC injection were measured by gen-
eral methods (10 rats of each group, including the nor-
mal control, diabetes control, and treatment groups).
Statistical Analysis
Numerical values are presented as the mean ± SD. Each
experiment was repeated three times. Statistical signifi-
cance was evaluated using unpaired Student’s t test for
comparisons between the two groups; p values <0.05 were
considered to be statistically significant. All statistical ana-
lyses were performed by the SPSS software package.
Results and Discussion
Preparation and Identification of MSCs
Rat MSCs were isolated and cultured. MSCs attached to
the culture flasks sparsely and displayed a fibroblast-like,
spindle-shaped morphology during the initial days of in-
cubation. After 3 ~ 4 days of incubation, proliferation
started and the cells gradually grew into small colonies.
One week later, colonies with different sizes increased in
number. As growth continued, adjacent colonies inter-
connected with each other and a monolayer confluence
was obtained after 12 ~ 15 days of incubation. In later
passages, MSCs exhibited large, flattened, or fibroblast-
like morphology (Fig. 1a, b).
To identify MSCs, phenotypes and multiple differenti-
ation capacities of cultured BM-derived adherent cells atvarious passage numbers. a During the onset of growth (P0-7th day),
ttened morphology. b In later passages (P4-4th day), most of these
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more than 95 % of these cells were positive for CD29,
CD90, but negative for CD31, CD45.
In order to confirm whether prepared MSCs could dif-
ferentiate into two lineages such as osteogenic and adipo-
genic lineages, we finished the differentiation ability
analysis of osteogenic and adipogenic differentiation
induction.
Firstly, osteogenic differentiation was induced in puta-
tive MSC lines by culturing cells in an osteo-inductive
medium. After 3 weeks in an inductive medium, the
treated population contained numerous positive cells
widely distributed in the dish and others grouped into col-
onies. Alizarin red staining of the extra-cellular calcium in
differentiated cells, as shown in Fig. 3a, indicated osteo-
genic differentiation of MSCs into osteoblasts.
Afterward, adipogenic differentiation of putative MSC
lines induced by using adipo-inductive media resulted in
massive lipid droplet accumulation as demonstrated by
positive staining with Oil Red O (Fig. 3b). Lipid dropletsFig. 2 Flow cytometry analysis of cell surface markers in MSCs at passage 3
profiling of MSC lines. Surface expressions of CD29, CD 31, CD45, and CD90
Calibur instrument with BD Cell Quest™ software and off-line analysis by uswere detectable even after 3 days, but a period of 2 weeks
was necessary to accomplish maximal lipid accumulation.
In addition, the differentiating abilities of osteogenic
and adipogenic lineages of MSCs were assessed in our
study as previously described (Fig. 3) [11]. These results
indicate that the cultured cells possessed the characteris-
tics of MSCs.Preparation and Characterization of CdSe/ZnS Quantum
Dots
As shown in Fig. 4a, synthesized CdSe/ZnS QDs exhib-
ited strong fluorescence signal and narrow emission
spectra. Figure 4b shows a typical TEM image of the
CdSe/ZnS QDs. The QDs have a narrow size distribu-
tion of 4.8 nm in diameter. The existence of lattice
planes on the HRTEM confirms the good crystallinity of
the CdSe/ZnS core–shell structure. With the ZnS coat-
ing, the emission peak of CdSe/ZnS appeared at the
wavelength of 655 nm. The shell could not only enhance. Fluorescence-activated cell sorting (FACS) analysis for surface antigen
on MSC lines and control cells were analyzed by using a BD FACS
ing Flowjo™ software (represented as blue filling)
Fig. 3 Osteogenic and adipogenic differentiation of MSCs. a Calcified colonies after osteogenic induction stained with alizarin red. b Lipid droplet
accumulated in an adipo-inductive medium stained with Oil Red O
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ity and decreased the cytotoxicity.Effects of CdSe/ZnS QDs on the Differential Ability of
MSCs
When the MSCs were differentiated under incubation with
16 μg/ml CdSe/ZnS QDs for 2 weeks, the morphology of
final cells were compared with the MSCs without QDs.
The compared results showed that the CdSe/ZnS QDs
had negligible effects on the differentiation ability of
MSCs in our experiment (Fig. 5a, b) similar to our pre-
vious report [9].Effects of CdSe/ZnS Quantum Dots on Viability of MSCs
QDs were transduced into MSCs at various concen-
trations in a transduction medium for 6 h at 37 °C.
Significant cytotoxicity was observed in MSCs trans-
duced with 32 or 50 μl/ml of QDs; however, in
addition, no remarkable cytotoxicity was observed,
and with less than 16.0 μl/ml of QDs, more than
80 % of the cells were still alive (Fig. 6). Therefore,
we chose the QD concentration of less than 16 μl/ml
to label the MSCs, so as to study the morphologyFig. 4 Characteristics of synthesized CdSe/ZnS quantum dots. a The absorb
represent absorbance (the curves from the upper left to the lower-middle par
an obvious protrusive shape) of the QDs at an emission peak of 655 nm. b T
core–shell QDsand fluorescence images with the help of conventional
fluorescence microscopy.Preparation and Observation of QDs-Labeled MSCs
After incubation with different concentrations of QDs
with MSCs for 4 h, the MSC-labeling efficiency was very
different, 15 μg/ml QDs exhibited maximal labeling effi-
ciency, and almost all MSCs exhibited strong red fluor-
escence signals, which showed that almost all MSCs
were successfully labeled with QDs. Increasing the con-
centration beyond 20 μg/ml did not increase the QD in-
ternalization, but the ratio of cell death began to rise
(Fig. 7). This result suggested that the optimal concen-
tration ratio of QDs was 15 μg/ml.
In order to investigate the mechanism of QD-
labeling MSC cells, as shown in Fig. 8, QDs were
endocytosed into MSCs, and located in the cytoplasm
around nucleus, QDs exhibited a strong red color
(Fig. 8b), and cell nucleuses exhibited a blue color
(Fig. 8c). The overlaid image (Fig. 8d) showed that
most of the quantum dots were located inside the
cytoplasm. With time elapsed, there were no QDs
exocytosised by MSCs, and QDs coexisted with MSCs
closely.ance and emission spectra of synthesized QDs. The blue lines
t) and the red lines represent the photoluminescence (the curves with
EM image of CdSe/ZnS QDs. Insets in b showed the HRTEM images of
Fig. 5 The differentiation ability variation of hMSCs with 16 μg/ml CdSe/ZnS QDs. a, c The morphology of the osteogenic and adipogenic
lineages differentiated from hMSCs under the condition of QDs. b, d. The morphology of the osteogenic and adipogenic lineages differentiated
from hMSCs without QDs
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To verify the treatment of mesenchymal stem cells, we
investigated the level of blood glucose after MSC injec-
tion (10 rats of each group, including the normal con-
trol, diabetes control, and treatment groups). As shown
in Fig. 9, FPG of rats in the normal control group main-
tained within the normal range. FPG of rats in theFig. 6 Cell viability assay was observed in MSCs transduced with
different concentrations of QDs for 24 h. The survival of MSCs
transduced with QDs is compared with non-transduction MSCs. The
data, all in triplicate, are shown as the mean ± SD values. *p < 0.05diabetic control group and MSC treatment group chan-
ged significantly. FPG in the diabetic control group and
MSC treatment group was higher than the normal con-
trol group and diabetic control group. The level of FPG
in the diabetic control group was significantly higher
than in the MSC treatment group (p < 0.05, 8 weeks
after MSC transplantation) (Fig. 9).In Vivo Imaging and Distribution of QDs-Labeled MSCs
After tail intravenous injection of CdSe/ZnS QDs-
labeled MSCs in the diabetes group and normal control
group, the fluorescence signals were observed in differ-
ent time points (1, 3, 6, and 12 h). As shown in Fig. 10a,
after CdSe/ZnS QDs-labeled MSCs were injected into
mice for 1 h, MSCs accumulated in the lungs and ab-
dominal cavity, and the fluorescence signal strength had
no significant difference between the normal control
group and diabetes group. After 3 h of injection, signifi-
cant MSC accumulation in the lungs can be observed in
both groups (Fig. 10b). Six hours later, the CdSe/ZnS
QDs-labeled MSCs were homed into the pathological
tissue of the pancreas and the strongest fluorescence in-
tensity can be captured. In the normal control group,
the MSCs were mainly accumulated in the liver. While
in diabetic mice, the dominant signals were in the pan-
creas (Fig. 10c). After injection for 12 h, the signals of
Fig. 7 The labeling efficiency of different concentrations of QDs on MSCs. Different amounts of QDs (100 μg/ml) (5, 10, 15, and 20 μl/ml) were
incubated with MSCs for 4 h to determine the optimal labeling efficiency. Bright-field images (left, a, c, e, g) and fluorescence images (right, b, d, f, h)
were taken under inverted fluorescence microscope. Circle 1 and circle 2 indicated the same cell image in bright-field and fluorescence background.
The remaining circle 3 and circle 4, circle 5 and circle 6, and circle 7 and circle 8 were respectively the same single-cell image under bright-field images
(left) and fluorescence images (right)
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group, but the signal intensity decreased obviously
(Fig. 10d).
Biodistribution of QDs-Labeled MSCs
As shown in Fig. 11a, five important organs (heart,
lungs, pancreas, spleen, and liver) were harvested andimaged in the Bruker In-Vivo F PRO system. The fluor-
escence images exhibited different intensities of fluores-
cence signals within and between the control and
experimental groups. The pancreas fluorescence signal
of diabetic rats was much higher than that of the control
groups. Meanwhile, in the control group, the strongest
signal of QDs was mainly accumulated in the liver. This
Fig. 8 Observation of QDs entering into MSCs. a Bright-field images of MSCs treated with QDs. b Fluorescence image of cytoplasm labeled by
QDs. c nucleus stained by DAPI. d The overlaid images was merged with ImageJ. Blue represents DAPI stained nucleus, and red represents QDs.
The four circles indicated the identical cells. Scale bars are 200 μm
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get and homing to the pathological pancreas initiatively,
play the important role in the treatment of diabetes.
After 6 h of MSC transplantation, in order to analyze
the accumulation ratio of QDs, the ratios of fluorescence
intensity (RFI) analysis was performed in five organs
(Fig. 11b). The RFI results showed that the RFI of MSCs
in the pancreas of diabetic rats was about 32 %, while that
in the normal control group rats was about 18 % (p < 0.05,
triplicate of each groups). However, the RFI of the liver in
the normal control group was much higher than that ofFig. 9 Blood glucose of the three groups for 8 weeks after MSC
treatments. We set the time when MSCs were injected as the start
of the study. The data, all in triplicate, are shown as the mean ± SD
values. *p < 0.05the diabetes group (p < 0.05, triplicate of each group).
These data suggest that in vivo MSCs can migrate and
enter into the pancreas tissues actively, can be introduced
for pathological imaging of the pancreas tissue, and de-
duce the therapeutic function initiatively.
Potential Mechanism
Previous studies have revealed that MSCs are capable of
reducing glucose levels in animals or subjects with type
1 diabetes [12]. The underlying mechanism of the thera-
peutic effect of MSCs on hyperglycemia might involve
islet regeneration [13]. Several studies highly indicate
that the unique immunomodulatory effects of MSCs
seemed to be closely associated with decreasing hyper-
glycemia. MSCs also exerted anti-inflammatory effects
that might be important in maintaining peripheral toler-
ance [14, 15].
In our study, the blood glucose of the normal control
group and MSC treatment group changed significantly
at 2 months after MSC injection. The FPG of the MSC
treatment group dropped more than 5 mmol/l, while the
diabetic control group and normal control group make
no difference at the beginning of the study, and this phe-
nemenon was similar to previous reports [16, 17].
In order to clarify the potential mechanism, we pre-
pared QDs-labeled MSCs and observed their in vivo dis-
tribution. QDs own obvious advantages compared with
traditional fluorescent dye molecules [18]. Specifically,
QDs have a broad absorption range from ultraviolet
(UV) to visible light, but exhibit distinct narrow emis-
sion spectrum, resistant to photochemical degradation;
Fig. 10 In vivo fluorescence imaging in different time points after tail vein injection of CdSe/ZnS QDs-labeled MSCs. a–d The time points of 1, 3,
6, and 12 h, respectively
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monitoring cell biological changes in vivo [19–21].
We selected SD rats to prepare a diabetes model [22–24].
With the help of the Bruker In-Vivo F PRO system, the
transplanted MSCs were observed to accumulate in the
liver in the normal control animals, few MSCs in the
pancreas tissues, and the RFI analysis showed that the
accumulation rate of MSCs in the liver was about 41 %.
While in diabetic rats, the accumulation rate of the
transplanted MSCs in the liver was decreased to about
32 %, and the accumulation rate in the pancreas in-
creased to about 32 %. Accordingly, distribution differ-
ence between the two groups should be closely
associated with pancreas injury, which also confirmsFig. 11 Fluorescence imaging of rats with diabetes transplanted with QDs-
organs of rats with diabetes. b The ratio of the fluorescence intensity (RFI)
by the total fluorescence intensity of all five organs (heart, lungs, pancreas,
group (multiplied by 100)that MSCs can target and accumulate to the injured
organ [10, 25–30]. Our results also indirectly suggest
that quantum dots do not alter the self-replication and
differentiation potential of MSCs [7, 31, 32] and exhibit
great potential in tracking MSCs in vivo [33].
Regarding the molecular mechanism of MSC homing,
the transplanted MSCs were observed to accumulate in
the liver in normal control, which may be caused by
Kupffer cells with strong phagocytosis in hepatic sinus-
oid [31, 34]. The accumulation of transplanted MSCs in
the pancreas of diabetic rats may be closely associated
with chemokines [35, 36]. Our previous studies confirmed
that CCL19/CCR7 and CXCL12/CXCR4 axis loops played
key roles in the targeting of MSCs to in vivo gastric cancerlabeled MSCs. a The ex vivo fluorescence images of five important
of each organ equals the fluorescence intensity of the organ divided
spleen, and liver) in the normal control group and MSC treatment
Liu et al. Nanoscale Research Letters  (2015) 10:265 Page 11 of 12[37–39]. Therefore, we predict that CCL19/CCR7 and
CXCL12/CXCR4 axis loops also may play key roles in the
targeting of MSCs to in vivo injured pancreas. The con-
crete mechanism is under way.
Conclusions
We investigated the behavior and organ-specific accu-
mulation of transplanted MSCs labeled with QDs in a
rat model of type 1 diabetes. Using the Bruker In-Vivo F
PRO system, the accumulation rate of MSCs in the pan-
creas of rats in the diabetes group was increased com-
pared with the normal control group. The MSC-injected
diabetic rat group displayed lower blood glucose levels.
Our results highly indicate that QDs-labeled MSCs can
target in vivo pancreatic tissues of diabetic rats, and de-
crease the blood glucose levels, and then, in vivo trans-
planted MSCs may own clinical therapeutic prospect to
diabetic patients.
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